Scios Inc. Announces Results of ASCEND Heart Failure Study at the Scientific Sessions of the American Heart Association

CHICAGO--(BUSINESS WIRE)--Scios Inc. announced today that the landmark investigational study of NATRECOR® (nesiritide) for the treatment of acutely decompensated heart failure (ADHF), ASCEND-HF, demonstrated no statistically significant difference from placebo in the co-primary endpoints of dyspnea, measured at six and 24 hours, or in the composite of heart failure re-hospitalizations and death during the first 30 days following treatment. Importantly, the study reinforced the safety profile of NATRECOR®, revealing no excess adverse effects on renal function or mortality.